

DAFTAR PUSTAKA

- Abe, A., Minaguchi, T., Ochi, H., Onuki, M., Okada, S., Matsumoto, K., Satoh, T., *et.al.* 2013. PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma. *Human Pathology*, 44 : 199–207
- Agaoglu, FY., Kovancilar, M., Dizdar, Y., Darendeliler, E., Holdenrieder, S., Dalay, N., Gezer, U. 2011. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. *Tumor Biol*, 32 : 583–588
- Ahmedin, J., Siegel, R., Xu, J., Ward, E., 2010, Cancer Statistics, *CA Cancer J Clin.*, 60 : 277–300.
- Akiyama-Abe, A., Minaguchi, T., Nakamura, Y., Michikami, H., Shikama, A., Nakao, S., *et al.* 2013. Loss of PTEN expression is an independent predictor of favourable survival in endometrial carcinomas., *British Journal of Cancer*, 109 (6) : pp. 1703–10.
- Ali, AY., Farrand, L., Kim, JY., Byun, S., Suh, JY., Lee, HJ., Tsangi, BK. 2012. Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum. *Ann. N.Y. Acad. Sci.*, 1271, Pages : 58–67
- American Cancer Society. 2011. *Global Cancer Fact & Figures 2011 (2nd Edition)*. American Cancer Society, Atlanta, GA, USA.
- An, HJ., Lee, YH; Cho, NH; Shim, JY; Kim, JY; Lee, C; Kim, SJ. 2002. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27. *Histopathology*; 41: pp. 437-445.
- Antolín, S., Calvo, L., Blanco-Calvo, M., Santiago, M. P., Lorenzo-Patiño, M. J., Haz-Conde, M., *et al.* 2015. Circulating miR-200c and miR-141 and outcomes in patients with breast cancer. *BMC Cancer*, 15 (1) : pp. 297.
- Armstrong, D. K. 2002. Relapsed Ovarian Cancer : Challenges and Management Strategies for a Chronic Disease. *The Oncologist*, 7 (suppl 5) : pp. 20–28.
- Aziz, FM. 2009. Gynecological Cancer in Indonesia. *J Gynecol Oncol*, 20(1):pp.8-10
- Batista, L., Bourachot, B., Mateescu, B., Reya, F., Mechta-Grigoriou, F. 2016. Regulation of miR-200c/141 expression by intergenic DNA-looping and transcriptional read-through. *Nature Communications*, 7 : 8959

- Bentwich, I; Avniel, A; Karov, Y; Aharonov, R; Gilad, S; Barad, O; Barzilai, A; Einat, P; Einav, U; Meiri, E; *et al.* 2005. Identification of hundreds of conserved and nonconserved human microRNAs. *Nat. Genet.* 37 : pp.766–770.
- Berek, JS; Fu, YS; Hacker, NF. 2002. Ovarian Cancer in Novak's Gynecology 13th Edition. Williams & Wilkins, Pennsylvania : pp.1245-1320.
- Bose S., Crane A., Hibshoosh H., Mansukhani M., Sandweis L., and Parsons R. 2002. Reduced expression of PTEN correlates with breast cancer progression. *Hum Pathol*, 33: pp.405-409.
- Brase, J. C., Johannes, M., Schlomm, T., Haese, A., Steuber, T., Beissbarth, T., *et al.* 2011. Circulating miRNAs are correlated with tumor progression in prostate cancer. *Int. J. Cancer*, 128 (3) : pp.608–616.
- Brennecke, J; Stark, A; Russell, RB; Cohen, SM. 2005. Principles of microRNA-target recognition. *PLoS Biol*, 3(3) : pp. 85.
- Buys, SS., Partridge, E., Black, A., *et al.*, 2011. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. *Journal of the American Medical Association*, 22 : pp.2295– 2302.
- Cao, Q., Lu, K., Dai, S., Hu, Y. and Fan, W. 2014. Clinicopathological and prognostic implications of the miR-200 family in patients with epithelial ovarian cancer. *Int J Clin Exp Pathol*, 7 (5) : pp.2392–2401.
- Carelle, N., Piotto, E., Bellanger, A., Germanaud, J., Thuillier, A., Khayat, D. 2002. Changing patient perceptions of the side effects of cancer chemotherapy. *Cancer*, 95 (1) : pp. 155–163
- Chan, HS., & Zhang, Z. 2009. Liaison amid disorder : non-native interactions may underpin long-range coupling in protein. *Journal of Biology*, 8(3) : pp.27.
- Charan, JB, Tamoghna. 2013. How to Calculate Sample Size for Different Study Design in Medical Research. *Indian J Psychol Med*, 35(2) : pp.121-126
- Chen, M., Nowak, DG., Trotman, LC. 2014. Molecular Pathways: PI3K Pathway Phosphatases as Biomarkers for Cancer Prognosis and Therapy. *Clin Cancer Res*, 20 (12) : pp 3057-3063

- Chen, Y., Zhang, L., Hao, Q. 2013. Candidate microRNA biomarkers in human epithelial ovarian cancer: systematic review profiling studies and experimental validation. *Cancer Cell International*, 13 : pp.86
- Chen, Y., Zheng, H., Yang, X., Sun, L., Xin, Y. 2004. Effects of mutation and expression of PTEN gene mRNA on tumorigenesis and progression of epithelial ovarian cancer. *Chin Med Sci J*, 19(1) : pp.25-30.
- Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, *et al.* 2011. Circulating Plasma MiR-141 Is a Novel Biomarker for Metastatic Colon Cancer and Predicts Poor Prognosis. *PLoS ONE*, 6(3) : pp.17745.
- Chim, SS., Shing, TK., Hung, EC., Leung, TY., Lau, TK., Chiu, RW., Lo, YM. 2008. Detection and characterization of placental microRNAs in maternal plasma. *Clin.Chem*, 54 : pp. 482–490.
- Church, JE., Qian, J., Kumar., *et al.* 2010. Inhibition of endothelial nitric oxide synthase by the lipid phosphatase PTEN. *Vascular Pharmacology*, 52 : pp. 191–198.
- Correia, Nadia C; Girio, Ana; Antunes, Ines; Martins, Leila R; Barata, Joao T. 2014. The Multiple Layer of Non-Genetic Regulation of PTEN Tumour Suppressor Activity. *European Journal of Cancer*, 50 : pp.216-225
- Dahlan, S. 2013. Besar Sampel dan Cara Pengambilan Sampel Dalam Penelitian Kedokteran dan Kesehatan. Jakarta : Salemba Medika
- Tjindarbumi, D., Mangunkusumo R. 2002. Cancer in Indonesia, Present and Future. *Jpn. J. Clin.Oncol*, 32 (suppl 1) : pp.17-21.
- Diener, Y; Walenda, T; Jost, E; Brummendorf, H; Bosio, A; Wagner, W; *et.al.* 2015. MicroRNA expression profiles of serum from patients before and after chemotherapy. *Genomics Data*; 6 : pp.125–127
- Douglas, H. dan Weinberg, R. A., 2011, “Hallmark of Cancer : The Next Generation”, *The Cell*, 144(5) : pp.646-674.
- Douglas D. Taylor dan Cicek Gercel-Taylor. 2008. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. *Gynecol Oncol*, 110 : pp.13–21

- Dovc-Drnovsek, T., Emersic, B., Rozman, P., Cerne, D., Lukac-Bajalo, Jana. 2008. Optimization of Purification of Human Cell-Free mRNA from Plasma. *Ann. N.Y. Acad. Sci.* 1137: pp.125–129
- Fabian, M.R., Sonenberg, N., Filipowicz, W., 2010. Regulation of mRNA Translation and Stability by microRNAs. *Annu Rev Biochem*, 79 : pp.351–379.
- Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S. C., Mathers, M., Rebelo, M., Parkin, D.M., Forman, D., Bray, F. Globocan. 2012. Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 : ARC Cancer Base No. 11 diakses dari <http://www.iarc.fr/en/publications/eresources/cancerbases/>.
- Fu, Guodong; Brikc, Jelena; Hayder, Heyam; Peng, Chun. 2013. MicroRNAs in Human Placental Development and Pregnancy Complications. *Int. J. Mol. Sci*, 14 : pp.5519-5544
- Furnari, FB; Hong-Lin; Su Huang, HJ; Cavenee, WK. 1998. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. *PNAS*, 94(23) : pp.12479–12484
- Gao, Y., B, Feng., Han, S., Zhang, K., Chen, J., Li, C., Wang, R., Chen L. 2016. The Roles of MicroRNA-141 in Human Cancers: From Diagnosis to Treatment. *Cell Physiol Biochem*, 38 : pp.427-448
- Garzon, R., Marcucci, G., Croce, CM. 2010. Targeting microRNAs in cancer : rationale, strategies and challenges. *Nat Rev Drug Discov*, 9(10) : pp.775-789
- Ge, Qinyu; Zhu, Yanan; Li, Hailing; Tian, Fei; Xie, XueYing; Bai, YunFei. 2015. Differential expression of circulating miRNAs in maternal plasma in pregnancies with fetal macrosomia. *Int. J. Mol. Med*, 35: pp.81-91
- George, G.P. dan Mittal, R.D. 2010. microRNAs : Potential Biomarker in Cancer. *Indian J of Clin Biochem*, (1) : pp. 4-14
- GLOBOCAN. 2012 : Estimated Cancer Incidence, Mortality, and Prevalence Worldwide in 2012. Diakses dari <http://globocan.iarc.fr/Pages/online.aspx>
- Goda G Muralidhar dan Maria V Barbolina. 2015. The miR-200 Family: Versatile Players in Epithelial Ovarian Cancer. *Int. J. Mol. Sci.* 16 : pp.16833-16847

- Gomes, CP; Andrade, L. 2006. PTEN and p53 expression in primary ovarian carcinomas: immunohistochemical study and discussion of pathogenetic mechanisms. *Int J Gynecol Cancer*, 16 (Suppl. 1) : pp.254–258
- Greco, S; Gorospe, M; Martelli F. 2015. Noncoding RNA in age-related cardiovascular disease. *Journal of Molecular and Cellular Cardiology*; 83 : pp.142-155
- Halvorsen OJ, Haukaas SA and Akslen LA. 2003. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. *Clin Cancer Res*; 9 : pp.1474-1479.
- Hammell, M., Long, D., Zhang, L., Lee, A., Carmack, S., Han, M., *et.al.* 2008. mirWIP: microRNA Target Prediction Based on miRNP Enriched Transcripts. *Nat Methods*, 5(9) : pp.813–819
- Hettinger K, Vikhanskaya F, Poh MK, Lee MK, de Belle I, Zhang JT, *et al.* 2007. C-Jun promotes cellular survival by suppression of PTEN. *Cell Death Differ*; 14 : pp.218–29
- Ho, Chih-Ming; Lin, Ming-Chieh; Huang, Shih-Hung; Huang-Chi-Jung; Lai, Hung-Cheng; Chien, Tsai-Yen; *et.al.* 2009. *PTEN* promoter methylation and LOH of 10q22–23 locus in *PTEN* expression of ovarian clear cell adenocarcinomas. *Gynecol Oncol*, 112(2) : pp.307–313
- Huang, L., Wang, HY., Li., JD., Wang, JH., Zhou, Y., Luo, RZ., *et.al.* 2013. KPNA2 promotes cell proliferation and tumorigenicity in epithelial ovarian carcinoma through upregulation of c-Myc and downregulation of FOXO3a. *Cell Death and Disease*, 4 : pp.745
- <http://mirtarbase.mbc.nctu.edu.tw/php/detail.php?mirtid=MIRT003281>(Diakses tanggal 21 Agustus 2015)
- http://www.targetscan.org/cgi-bin/targetscan/vert_70/view_gene.cgi?rs=ENST00000371953.3&taxid=9606&showcnc=0&shownc=0&shownc_nc=&showncf=&subset=1#miR-141-3p/200a-3p (Diakses tanggal 21 Agustus 2015)
- <http://www.microrna.org/microrna/getMrna.do?gene=5728&utr=12162&organism=9606#> (Diakses tanggal 21 Agustus 2015)

- Iorio, MV; Visone, R; Di Leva, G; Donati, V; Petrocca, F; Casalini, P; *et al.* 2007. MicroRNA signatures in human ovarian cancer. *Cancer Res*, 67 : pp.8699–707.
- Jaime Prat. FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: a bridged republication. 2015. *Gynecol Oncol*, 26 (2) : pp.87-89
- Jelovac, D; Armstrong, DK. 2011. Recent Progress in the Diagnosis and treatment of Ovarian Cancer. *Ca Cancer J Clin*, 61 : pp.183–203
- Jia-Ling Teo dan Michael Khan. 2010. The Wnt signaling pathway in cellular proliferation and differentiation: A tale of two coactivators. *Advanced Drug Delivery Reviews*; 62 : pp.1149–1155
- Kaku, Tsunehisa; Ogawa, Shinji; Kawano, Yoshiaki; Ohishi, Yoshihiro; Kobayashi, Hiroaki; Hirakawa, Toshio; Nakano, Hitoo 2003. Histological classification of ovarian cancer. *Med Electron Microsc*, 36 : pp.9–17
- Kaye SB. 2008. Reversal of drug resistance in ovarian cancer: where do we go from here?. *J Clin Oncol*, 26 : pp.2616–8.
- Kinose, Y; Sawada, K; Nakamura, K; Kimura, T. 2014. The Role of MicroRNA in Ovarian Cancer. *Biomed Research International*, 2014
- Kosaka, Nobuyoshi; Iguchi, Haruhisa; Ochiya, Takahiro. 2010. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. *Cancer Sci*, 101 (10) : pp.2087–2092
- Krol, J; Loedige, I; Filipowicz, W. 2010. The widespread regulation of microRNA biogenesis, function, and decay. *Nature Reviews Genetic*, 11 (9) : pp. 597-610
- Kurose, Keisuke; Zhou, Xiao-Ping; Araki, Tsutomu; Cannistra, Stephen A; Maher, Eamonn R; Eng, Charis. 2001. Frequent Loss of PTEN Expression Is Linked to Elevated Phosphorylated Akt Levels, but Not Associated with p27 and Cyclin D1 Expression, in Primary Epithelial Ovarian Carcinomas. *The American Journal of Pathology*, 158 (6) : pp.2097–2106
- Li, H; Tang, J; Lei, H; Cai, P; Zhu, H; Li, B; Xu, X; Xia, Y; Tang, W. 2014. Decreased MiR-200a/141 suppress cell migration and proliferation by targeting PTEN in Hirschsprung's disease. *Cell Physiol Biochem*. 34 (2) : pp.543-53
- Li, Wei; Di, Wu; Hua, Lijuan; Zhou, Bingrong; Guo, Ze; Luo, Dan. 2011. UVB suppresses PTEN expression by upregulating miR-141 in HaCaT cells. *Journal of Biomedical Research*, 25(2) : pp.135-140

- Li, M., Marin-Muller, C., Bharadwaj, U., Chow, KH., Yao, Q., Chen, C. 2009. microRNAs : control and loss of control in human physiology and disease. *World J Surg*, 33(4) : pp.667-84
- Li, J; Yen, C; Liaw, D; Podsypanina, K; Bose, S; Wang, SI; Puc, J; Miliaresis, C; Rodgers, L; McCombie, R; Bigner, SH; Giovanella, BC; Ittmann, M; Tycko, B; Hibshoosh, H; Wigler, MH; Parsons, R. 1997. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. *Science*. 28; 275(5308) : pp.1943-7.
- Lima, RT; Busacca, S; Almeida, GM; Gaudino, G; Fennel, DA; Vanconcelos, MH. 2011. MicroRNA regulation of core apoptosis pathway in cancer. *European Journal of Cancer*. 47(2) : pp.163-74
- Lingel, A; Simon, B; Izaurralde, E; Sattler, M. 2003. Structure and nucleic-acid binding of the Drosophila Argonaute 2 PAZ domain. *Nature*, 426 : pp. 465–469
- Lisa Gunawan. 2015. *Ekspressi MicroRNA BART-7-3p Dan mRNA PTEN Pada Plasma Darah Pasien Karsinoma Nasofaring*. Tesis S2 Bioteknologi Universitas Gadjah Mada Yogyakarta.
- Liu, Michelle X; Chan, David W; Ngan, Hextan YS. 2012. Mechanisms of Chemoresistance in Human Ovarian Cancer at a Glance. *Gynecol Obstet*, 2 : 3
- Lodes, MJ; Caraballo, M; Suci, D; Munro, S; Kumar, A; Anderson, B. 2009. Detection of cancer with serum miRNAs on an oligonucleotide microarray. *PLoS ONE*, 4 : pp.6229
- Lu J, Jeong HW, Kong N, Yang Y, Carroll J, Luo HR, *et al*. 2009. Stem cell factor SALL4 represses the transcriptions of PTEN and SALL1 through an epigenetic repressor complex. *PLoS One*, 4 : e5577
- Maehama, T; Dixon, JE. 1998. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. *J Biol Chem*. 29 ; 273(22) : pp.13375-8.
- Mahdavinezhad, A; Mousavi-Bahar, SH; Poorolajal, J; Yadegarazari, R; Jafari, M; Shahab, N; Saidijam, M. 2015. Evaluation of miR-141, miR-200c, miR-30b Expression and Clinicopathological Features of Bladder Cancer. *Int J Mol Cell Med Winter*, 4(1) : pp.32-39

- Mahdavinezhad, Ali *et al.* 2015. Association between Tissue miR-141, miR-200c and miR-30b and Bladder Cancer: A Matched Case-Control Study. *Urological Oncology*, 12 (1).
- Mao, F., Leung, WY., Xin, X. 2007. Characterization of EvaGreen and the implication of its physicochemical properties for qPCR applications. *BMC Biotechnology*, 7 : 76
- McMenamin, Mairin E; Soung, Peggy; Perera, Sauni; Kaplan, Irving; Loda, Massimo; Sellers, William R. 1999. Loss of PTEN Expression in Paraffin-embedded Primary Prostate Cancer Correlates with High Gleason Score and Advanced Stage. *Cancer Research*, 59 : pp.4291–4296
- Mei, Z., He, Y., Feng, J., Shi, J., Du, Y., Qian, L., Huang, Q., Jie, Z. 2014. MicroRNA-141 promotes the proliferation of non-small cell lung cancer cells by regulating expression of PHLPP1 and PHLPP2. *FEBS Lett*; 588 : pp.3055-3061.
- Menor, M., Ching, T., Zhu, X., Garmire, D., Garmire, LX. 2014. mirMark: a site-level and UTR-level classifier for miRNA target prediction. *Genome Biology*, 15 : pp.500
- Morales-Prieto, D.M.; Schleussner, E.; Markert, U.R. 2011. Reduction in miR-141 is induced by leukemia inhibitory factor and inhibits proliferation in choriocarcinoma cell line JEG-3. *Am. J.Reprod. Immunol*, 66 : 57–62.
- Morgan, JR; Alvarez, DR; Copeland, L; Fowler, J; Soper, J; Greshenson, D. 2006. Ovarian Cancer, NCCN Clinical Practice Guidelines in Oncology
- Nakanishi, A; Wada, Y; Kitagishi, Y; Matsuda, S. 2014. Link between PI3K/AKT/PTEN pathway and NOX protein in diseases. *Aging Dis*, 5 : 203–11.
- Nakanishi, Atsuko; Kitagishi, Yasuko; Ogura, Yasunori; Matsuda, Satoru. 2014. The Tumor Suppressor PTEN Interacts with p53 in Hereditary Cancer (Review). *International Journal; of Oncology*, 44 : 1813-1819
- Nam, EJ; Yoon, HY; Kim, SW; *et al.* 2008. MicroRNA expression profiles in serous ovarian carcinoma. *Clinical Cancer Research*, 14(9) : pp.2690–2695.
- Nguyen, L; Cardenas-Goicoechea, SJ; Gordon, P; Curtin, C; Momeni, M; Chuang, L; *et.al.* 2013. Biomarkers for early detection of ovarian cancer. *Women's Health*, 9(2) : pp.171-187

- Nicolleta Colombo. 2014. Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient. *European Journal of Cancer Supplements*. 12(2) : pp.7–12
- Nick R Leslie dan C Peter Downes. 2004. PTEN Function : How Normal Cells Control it and Tumour Cell Loss it. *Biochem. J*, 382 : 1–11
- O'Carroll, D; Schaefer, A. 2013. General principals of miRNA biogenesis and regulation in the brain. *Neuropsychopharmacology*, 38(1) : 39-54.
- Parolini, I; Federici, C; Raggi, C; Lugini, L; Lugini, L; Palleschi, S; *et.al*. 2009. Microenvironmental pH is a key factor for exosome traffic in tumor cells. *J Biol Chem*, 284 : 34211-22.
- Pedro M Costa dan Maria C Pedroso de Lima. 2013. MicroRNAs as Molecular Targets for Cancer Therapy: On the Modulation of MicroRNA Expression. *Pharmaceutics*, 6(10) : 1195–1220
- Piccart, MJ; Bertelsen, K; James, K; *et al*. 2000. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. *J Natl Cancer Inst*, 92 : 699-708
- Pi-Lin, S; Yen-Hou, C; Kuan-Chong, C; Chi-Mu, C. 2014. Global distribution pattern of histological subtypes of epithelial ovarian cancer: A database analysis and systematic review. *Gynecologic Oncology*, 133 : 147–154
- Planchon, SM., Waite, KA., Eng, C. 2008. The Nuclear Affairs of PTEN. *Journal of Cell Science*, 121 : 249-253
- Poliseno, L; Salmena, L; Zhang, J; Carver, B; Haveman, WJ; Pandolfi, PP. 2010. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. *Nature*, 465 : 1033–8
- Prat, J. 2012. New Insight Into Ovarian Cancer Pathology. *Annals of Oncology*, 23(10) : 111-117
- Pritchard, CC., Cheng, HH., Tewari, M. 2012. microRNA profiling : approaches and considerations. *Nat Rev*. 13 : 358-69
- Ren, WH; Qiang, C; Gao, L; Li, SM; Zhang, LM; Wang, XL; *et.al*. 2014. Circulating microRNA-21 (MIR-21) and phosphatase and tensin homolog (PTEN) are

promising novel biomarkers for detection of oral squamous cell carcinoma. *Biomarkers*, 19(7) : 590–596

Robert F Ozols. 2002. Recurrent Ovarian Cancer: Evidence-Based Treatment. *Journal of Clinical Oncology*, 20(5) : 1161-1163

Rodriguez, S; Hyunh-Do, U. 2012. The Role of PTEN on Tumor Angiogenesis. *Journal of Oncology* : Pages 1-11

Rosen, DG; Yang, GL; Guangzhi; Mercado-Uribe, I; Chang, B; Xoi, XZ; *et.al*. 2010. Ovarian cancer: pathology, biology, and disease models. *Front Biosci*, 14 : 2089-2102

Ruly Widagdo. 2009. *Angka Harapan Hidup Penderita Kanker Ovarium di Rumah Sakit Sardjito*. Tesis Fakultas Kedokteran Universitas Gadjah Mada

Rusnita, T; Prijono, I. Ekspresi P53, Bcl-2 dan Nm23-H1 pada Karsinoma Ovarium Tipe Serosum dan Musinosum serta Hubungannya dengan Stadium dan Derajat Histologi. *Majalah Patologi*; 23(2) : 13-19

Salehi, F; Dunfield, L; Krewski, D; Vanderhyden, BC. 2008. Risk factors for ovarian cancer: an overview with emphasis on hormonal factors. *J Toxicol Environ Health B Crit Rev*. 11(3-4) : 301-21.

Sari, Dwi Nur Indah. (2015). Ekspresi miRNA-155 dan mRNA Suppressor of Cytokine Signaling-1 (SOCS-1) pada Plasma Darah Pasien Kanker Payudara Ditinjau dari Status Klinikopatologis dan Molekuler. Tesis S2 IKD dan Biomedis Fakultas Kedokteran UGM

Schwarzenbach, Heidi; Nishida, Naohiro; Calin, George A; Pantel, Klaus. 2014. Clinical Relevance of Circulating Cell-Free microRNA in Cancer. *Nature Review Clinical Oncology*, 11 : 145-156

Seidman, JD; Horkayne-Szakaly, I; Haiba, M; *et al*. 2004. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. *Int J Gynecol Pathol*, 23 : 41–4.

Shen, Y; Shen, R; Ge, L; Zhu, Q; Li, F. 2012. Fibrillar Type I Collagen Matrices Enhance Metastasis/Invasion of Ovarian Epithelial Cancer Via A1 Integrin and PTEN Signals. *Int J Gynecol Cancer*, 22 : 1316-1324

Siegel, RL; Siegel, KD. Miller, A. Jemal. 2015. Cancer statistics, 2015. *CA Cancer J. Clin*, 65 (1) : pp.5–29

- Siegel, R; Ma, J; Zou, Z; Jemal, A. 2014. Cancer statistics, 2014. *CA: Cancer Journal for Clinicians*, 64(1) : pp.9–29
- Sopik, V; Iqbal, J; Rosen, B; Narod, SA. 2015. Why have ovarian cancer mortality rates declined Part I. Incidence. *Gynecol Oncol*, 138(3) : 741-9
- Soria, JC; Lee, HY; Lee JI; *et al.* 2002. Lack of PTEN expression in nonsmall cell lung cancer could be related to promoter methylation. *Clin Cancer Res*, 8: 1178-1184
- Soslow, A Robert. 2008. Histologic Subtypes of Ovarian Carcinoma: An Overview. *International Journal of Gynecological Pathology*, 27 : 161–174
- Stahl, M; Dijkers, PF; Kops, GJPL; Lens, SMA; Coffey, PJ; Burgering, BMT; *et.al.* 2002. The Forkhead Transcription Factor FoxO Regulates Transcription of *p27^{kip1}* and Bim in Response to IL-2. *The Journal of Immunology*, 168 : 5024-5031
- Stiles, Bangyan; Groszer, Matthias; Wang, Shunyou; Jiao, Jing; Wu, Hong. 2004. PTENless means more. *Developmental Biology*, 273 : 175– 184
- Sui, L; Dong, Y; Watanabe, Y; Yamaguchi, F; Sugimoto, K; Tokuda, M. 2006. Alteration and clinical relevance of PTEN expression and its correlation with survivin expression in epithelial ovarian. *Oncology Report*; 15 : 773-778
- Suzuki, H., Maruyama, R., Yamamoto, E., Kai, M. 2012. DNA methylation and microRNA dysregulation in cancer. *Molecular oncology*, 6 : 567-578.
- Trotman, LC; Wang, X; Alimonti, A; Chen, Z; Teruya-Feldstein, J; Yang, H; *et al.* 2007. Ubiquitination regulates PTEN nuclear import and tumor suppression. *Cell*, 128 : 141–56
- Valadi, H; Ekstrom, K; Bossios, A; Sjostrand, M; Lee, JJ; Lotvall, JO. 2007. Exosome mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol*, 9 : 654–659.
- Van Jaarsveld, MTM; Helleman, J; Boersma, AWM; Van Kuijk, PF; Van Ijcken, WF; Despierre, E; *et al.* 2013. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. *Oncogene*, 32 : 4284-4293

- Vara, JAF; Casado, E; Castro, JD; Cejas, P; Belda-Iniesta, C; Gonzales-Baron, M. 2004. PI3K/Akt signalling pathway and cancer. *Cancer Treatment Review*, 30 : 193–204
- Vasudevan, KM; Gurumurthy, S; Rangnekar, VM. 2004. Suppression of PTEN expression by NF-kappa B prevents apoptosis. *Mol Cell Biol*, 24 : 1007–21
- Vester, B dan Wengel, J. 2004. LNA (Locked Nucleic Acid) : High Affinity Targeting of Complementary RNA and DNA. *Biochemistry*, 23(42) : 13233-40
- Vinciguerra, M; Carrozzino, F; Peyrou, M; Carlone, S; Montesano, R; Benelli, R; *et.al.* 2009. Unsaturated fatty acids promote hepatoma proliferation and progression through downregulation of the tumor suppressor PTEN. *Journal of Hepatology*, 50 : 1132-1141
- Vrba, L; Jensen, TJ; Garbe, JC; Heimark, RL; Cress, AE; Dickinson, S; *et al.* Role for DNA Methylation in the Regulation of miR-200c and miR-141 Expression in Normal and Cancer Cells. *PLoS ONE*, 5(1) : e8697.
- Wang, L., Wang, C., Jin, S., Donghui, Q., Huanchun, Y. 2015. Expression of NF-κB and PTEN in primary epithelial ovarian carcinoma and the correlation with chemoresistance. *Int J Clin Exp Pathol*, 8(9) : 10953-10963
- Wang, WT; Zhao, YN; Yan, JX; Weng, MY; Wang, Y; Chen, YQ; *et.al.* 2014. Differentially expressed microRNAs in the serum of cervical squamous cell carcinoma patients before and after surgery. *Journal of Hematology and Oncology*, 7 : 6
- Wang, J; Zhang, KY; Liu, SM; Sen, S. 2014. Tumor-Associated Circulating MicroRNAs as Biomarkers of Cancer. *Molecules*, 19 : 1912-1938
- Wen-Tao, W. dan Chen, Y-Q., 2014, Circulating miRNAs in Cancer : from Detection to Therapy. *Journal of Hematology and Oncology*, 7 : 86
- Whiteman, D. C., Zhou, X. P., Cummings, M. C., Pavey, S., Hayward, N. K. and Eng, C. 2002. Nuclear PTEN expression and clinicopathologic features in a population based series of primary cutaneous melanoma. *Int. J. Cancer*. 99 : 63-67.
- William, C.S, Cho. 2011. MicroRNAs in Cancer Translational Research. New York : Springer.

- Winter, J; Jung, S; Keller, S; Gregory, RI; Diederichs, S. 2009. Many roads to maturity: microRNA biogenesis pathways and their regulation. *Nat Cell Biol.* 11(3) : 228-34
- Xiao, J., Gong, AY., Eischeid, AN., Chen, D., Deng C., Young, CY., *et.al.* 2012. MiR-141 modulates androgen receptor transcriptional activity in human prostate cancer cells through targeting the small heterodimer partner protein. *Prostate*; 72 : 1514-1522.
- Yap, TA; Carden, CP; Kaye, SB. 2009. Beyond chemotherapy : targeted therapies in ovarian cancer. *Nat Rev Cancer*, 9 : 167-181
- Yhing-chun Gao dan Jie Wu. 2015. MicroRNA-200c and microRNA-141 as potential diagnostic and prognostic biomarkers for ovarian cancer. *Tumor Biology*
- Yin, Y and Shen, WH. 2008. PTEN : a new guardian of the genome. *Oncogene*, 27 : 5443–5453
- Yuan, XJ; Whang, YE. 2002. PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. *Oncogene*, 21 : 319–27.
- Yuang, J., Wang, K., Mingrong Xi. 2016. MiR-494 Inhibits Epithelial Ovarian Cancer Growth by Targeting c-Myc. *Med Sci Monit.* 22 : 617–624
- Yudha Bintoro S. (2015). *Perbedaan Hsa-miR-21-5p dan mRNA PTEN Berdasarkan Stadium Klinis Pada Plasma Darah Pasien Karsinoma Nasofaring*. Tesis S2 IKD dan Biomedis Fakultas Kedokteran UGM
- Zernecke, A; Bidzhekov, K; Noels, H; *et al.* 2009. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. *Sci Signal*, 2 : ra81.
- Zhang, HL., Qin, XJ., Cao, DL., Zhu, Y., Yao, XD., Zhang, SL., *et.al.* 2013. An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions. *Asian J Androl*, 15 : 231-235.
- Zhang, L; Deng, T; Li, X; Liu, H., Zhou, H; Ma, J; *et al.* 2010. microRNA-141 is involved in a nasopharyngeal carcinoma-related genes network. *Carcinogenesis*, 31 (4) : 559–566

Zheng, H; Zhang, L; Zhao, Y; Yang, D; Song, F; Wen, Y; *et.al.* 2013. Plasma miRNAs as Diagnostic and Prognostic Biomarkers for Ovarian Cancer. *Plos One*, 8(11)

Zuberi, M., Mir, R., Dholariya, S., Najar, I.,Yadav, P., Javid, J., *et.al.* 2014. *RASSF1* and *PTEN* Promoter Hypermethylation Influences the Outcome in Epithelial Ovarian Cancer. *Clinical Ovarian and Other Gynecologic Cancer*, 7 : 33–39